Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited has announced a series of offers for new options to Placement Subscribers, Directors, and pursuant to Share Subscription Agreements with Lantheus, with exercise prices ranging from A$0.05 to A$0.06 and expiry dates up to August 2026. These offers, considered speculative, form part of a transaction-specific prospectus under the Corporations Act and are restricted outside Australia, closing on 21 August 2024.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
